Health and Healthcare
Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study
Published:
Last Updated:
Eli Lilly and Co. (NYSE: LLY) announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the Fifth Annual Maui Derm NP+PA Fall meeting. A total of 1,027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of Taltz compared to Tremfya.
Specifically, this data comes from Eli Lilly’s Phase 4 study, which was the first head-to-head study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) as the primary endpoint.
Taltz met the primary endpoint of superiority over Tremfya in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance as measured by PASI 100 at Week 12 (41.3% versus 24.9%).
Additionally, all major secondary endpoints up to Week 12 were achieved. Key secondary endpoints included superiority over Tremfya in the proportion of patients achieving PASI 75 at Week 2, PASI 90 at Weeks 4 and 8, PASI 100 at Weeks 4, 8 and 24.
Taltz is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.
Andrew Blauvelt, lead study investigator, M.D., M.B.A., dermatologist and president of Oregon Medical Research Center, commented:
Healthcare providers and patients value speed of response when evaluating treatment options for moderate to severe plaque psoriasis. The results from the IXORA-R study demonstrate that Taltz was effective in helping more patients achieve completely clear skin by Week 12, with a 50 percent improvement in skin plaques seen as early as Week 1.
Shares of Eli Lilly traded at $107.00, in a 52-week range of $104.17 to $132.13. The consensus price target is $124.25.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
